Neoantigen × AI
Daily research signal
TRACKING / TRIAL TRACKER

NCT07930338 — YGION Biomedical cancer immunotherapy trial

First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma

TrackingPhase 1Not Yet RecruitingRegistry updated 12 Nov 2026
Phase 1phaseNot Yet Recruitingregistry status15enrollment2028-04primary completion

Registry IDNCT07930338 ↗
Lead sponsorYGION Biomedical GmbH
Collaborators—
PhasePhase 1
StatusNot Yet Recruiting
IndicationGlioblastoma
Enrollment15 participants (target)
Start date2026-11
Primary completion2028-04 (est.)
Last registry update12 Nov 2026

Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07930338), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.

Daily coverage of the modality, tumor type and players this study touches:

What phase is NCT07930338?

NCT07930338 (First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by YGION Biomedical GmbH.

Is NCT07930338 recruiting?

As of the 2026-11-12 registry update, NCT07930338 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.

Who is running NCT07930338?

The lead sponsor is YGION Biomedical GmbH.

What condition does NCT07930338 study?

The registered condition is Glioblastoma. Primary completion is listed as 2028-04 (estimated).

Are results available for NCT07930338?

neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07930338.

Back to the full neoantigen vaccine trial tracker — 105 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.